Hunan Jiudian Pharmaceutical Co Ltd

Jiudian Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 160 million yuan, a decrease of 45.21% compared with the same period last year. Total operating revenue was 1.287 billion yuan, down 14.89% year-on-year; net cash inflow from operating activities was 307 million yuan. The latest gross margin was 64.26%, a decrease of 10.32 percentage points from the same period last year; the latest return on equity was 6.15%, down 5.10 percentage points year-on-year. Diluted earnings per share were 0.40 yuan, down 32.20% year-on-year.

Jiudian Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 160 million yuan, down 45.2% year on year. Operating revenue was 1.29 billion yuan, down 14.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 149 million yuan, down 47.3% year on year. Net operating cash flow was 307 million yuan, up 11.4% year on year. Second-quarter operating revenue was 692 million yuan, down 15.2% year on year, and net profit attributable to the parent was 103 million yuan, down 37.9% year on year. The company said the biomedical industry is showing structural recovery and divergence, that the market share of its leading product loxoprofen sodium gel patch remains stable, and that it is continuing to advance its strategic transformation toward innovative drugs.

Jiudian Pharmaceutical announced that its products ferrous succinate tablets and indobufen tablets have been tentatively selected for the 12th national centralized drug procurement. Ferrous succinate tablets were approved for market in September 2019, with 2025 sales revenue of 52.22 million yuan, accounting for 1.68% of the company's operating revenue in the same period. Indobufen tablets were approved for market in September 2024, with no sales in 2025 and the first quarter of 2026. In the first quarter of 2026, Jiudian Pharmaceutical achieved revenue of 595 million yuan and net profit attributable to the parent company of 56.74 million yuan.